Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 12/20 | 0.78 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.77 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.77 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.71 |
| ▸ | ANPEP | P15144 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29619763 | 0.94 | AGTR1 (0.75) | RENAGTR2AGTR1LNPEPANPEP | |
| Angiotensin Iv SCHEMBL27169570 | 0.93 | LNPEP (0.82) | RENAGTR2AGTR1LNPEPANPEP | |
| Angiotensin Iv SCHEMBL10066237 | 0.93 | LNPEP (0.82) | RENAGTR2AGTR1LNPEPANPEP | |
| SCHEMBL4738788 | 0.89 | AGTR1 (0.69) | RENAGTR2AGTR1LNPEPANPEP | |
| SCHEMBL31332289 | 0.88 | AGTR2 (0.91) | RENAGTR2AGTR1LNPEP | |
| SCHEMBL28485749 | 0.88 | AGTR2 (0.94) | AGTR2AGTR1 | |
| SCHEMBL29770563 | 0.88 | LNPEP (0.74) | RENAGTR2AGTR1LNPEPANPEP | |
| SCHEMBL29394721 | 0.87 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL21811603 | 0.87 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL29619824 | 0.87 | AGTR2 (0.94) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000943-A1 | METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF | Synaptogenix, Inc. (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000943-A1 | METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF | GAP43, SNAP29, SYNGR2 | REN 53/4885AGTR2 79/4885AGTR1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.